Innate Pharma S.A.Innate Pharma S.A.Innate Pharma S.A.

Innate Pharma S.A.

No trades
No trades

Compare with Innate Pharma S.A.


Market capitalization
‪167.32 M‬USD
−0.61USD
‪−55.50 M‬USD
‪3.15 M‬USD
Beta (1Y)
1.33
Next report date
Report period
EPS estimate
Revenue estimate

Details


CEO
Jonathan Dickinson
Headquarters
Marseille
Founded
1999
IPO date
Oct 31, 2006
ISIN
US45781K2042
CUSIP
45781K204
FIGI
BBG009ZCBVG7
Identifiers
ISIN US45781K2042
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.